Related Experiment Video
Updated: Jun 19, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Novel orally active morpholine N-arylsulfonamides gamma-secretase inhibitors with low CYP 3A4 liability
Hubert Josien1, Thomas Bara, Murali Rajagopalan
1Department of CV and CNS Medicinal Chemistry, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA. hubert.josien@spcorp.com
Abstract:
A new class of 2,6-disubstituted morpholine N-arylsulfonamide gamma-secretase inhibitors was designed based on the introduction of a morpholine core in lieu or piperidine in our lead series. This resulted in compounds with improved CYP 3A4 profiles. Several analogs that were active at lowering Abeta levels in Tg CRND8 mice upon oral administration were identified.
More Related Videos
Related Concept Videos
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Antiviral Nucleoside Inhibitors
Cholinergic Antagonists: Pharmacokinetics
Anthelminthic Agents
Inhibitors of Bacterial DNA Synthesis

